The US Food and Drug Administration (FDA) appears to be taking a cautious, deliberative approach as it approaches the myriad of scientific and regulatory issues involving nanobiotechnology and nanomedicine.
If, like other readers, your top priority is to accelerate the drug discovery and development process, we have some new features in this issue to help you find information faster.
As more drug discovery and development processes cross borders, drug researchers must make sure that drug safety does not get lost in translation.
When researchers discovered that some genes could produce multiple forms of mRNA, they thought the phenomenon was rare. Now, alternative splicing of gene transcripts may be the rule, not the exception, and genomics researchers need to adapt their experimental strategies.
As they learn more about the genetic reasons for aging and cell death, researchers have already made aging a "curable disease" in model organisms. If similar successes can be achieved in humans, science will once again confront an ethical barrier.
PK/PD scientists are using computer-assisted modeling more than ever.
With the discovery of RNAi in the late 1990s, researchers had a whole new collection of experimental and therapeutic tools. Recent work on microRNA is now uncovering a surprising new level of natural gene regulation.
G&P June, 2005 Editorial
Despite constraints, the solid commitment of federal funding, along with a willing army of code contributors, bode well for the future of open-source bioinformatics. However, standardization and quality control remain concerns for this decentralized phenomenon.
Computational methods that can predict the structure of a protein from its amino acid sequence are improving. Developers of such programs say that the technology may one day completely supplant experimental structure determination.
Biologists rely on experimentally accessible model organisms to study aspects of anatomy, physiology, disease, and genetics. With high-throughput sequencing, scientists now have the ability to compare these diverse models at the molecular level.
G&P July/August, 2005 editorial
Industry and researchers are striving to miniaturize, both as a necessity and as a way to cut costs. Microfluidics, generally seen as microscopic versions of valves and channels, is coming into its own as new and innovative applications are developed.
Now more than ever, mass spectrometry, with new choices for automation, accessibility, convenience, and sheer power, eclipses all other methods for rapidly and accurately characterizing a metabolome, across a wide range of organisms and subspecialties.
For years, geneticists have had to rely on microsatellites—small pieces of repetitive DNA—to map human genotypes. Now, tools based on single nucleotide polymorphisms allow researchers to determine genotypes faster, more reliably, and in more detail than ever before.